Favipiravir, an antiviral for COVID-19?
作者信息
Coomes Eric A, Haghbayan Hourmazd
机构信息
Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Division of Cardiology, London Health Sciences Centre, Western University, London, Ontario, Canada.
出版信息
J Antimicrob Chemother. 2020 Jul 1;75(7):2013-2014. doi: 10.1093/jac/dkaa171.
Abstract
摘要
相似文献
1
Favipiravir, an antiviral for COVID-19?法匹拉韦，一种用于治疗新冠肺炎的抗病毒药物？
J Antimicrob Chemother. 2020 Jul 1;75(7):2013-2014. doi: 10.1093/jac/dkaa171.
2
Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy.将突变灾难视为一种潜在的新冠病毒治疗策略。
Heredity (Edinb). 2020 May;124(5):619-620. doi: 10.1038/s41437-020-0314-z. Epub 2020 Apr 6.
3
Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.口服法匹拉韦治疗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒RNA清除延迟患者：病例系列
Crit Care. 2020 Sep 25;24(1):578. doi: 10.1186/s13054-020-03288-5.
4
Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.法维拉韦与其他抗病毒药物或 COVID-19 治疗标准药物的比较：一项快速系统评价和荟萃分析。
Virol J. 2020 Sep 24;17(1):141. doi: 10.1186/s12985-020-01412-z.
5
A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.一项评估法匹拉韦和羟氯喹联合治疗中重度 COVID-19 住院成人的疗效和安全性的随机对照研究：研究方案的结构化总结。
Trials. 2020 Oct 31;21(1):904. doi: 10.1186/s13063-020-04825-x.
6
An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.一项针对 COVID-19 感染的抗病毒药物的适应性随机安慰剂对照 II 期试验（VIRCO）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 13;21(1):847. doi: 10.1186/s13063-020-04766-5.
7
Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2.关于法匹拉韦重新用于对抗新型冠状病毒的系统评价。
Mymensingh Med J. 2020 Jul;29(3):747-754.
8
The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.新型冠状病毒病患者核酸检测由阴转阳的机制及临床转归和法匹拉韦的疗效：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 5;21(1):488. doi: 10.1186/s13063-020-04430-y.
9
A Favipiravir-induced Fever in a Patient with COVID-19.一名新冠肺炎患者出现法匹拉韦诱发的发热
Intern Med. 2020;59(22):2951-2953. doi: 10.2169/internalmedicine.5394-20. Epub 2020 Nov 15.
10
Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019.在使用法匹拉韦治疗冠状病毒病2019期间发生的急性痛风性关节炎
Intern Med. 2020 Sep 15;59(18):2327-2329. doi: 10.2169/internalmedicine.5377-20. Epub 2020 Jul 28.
引用本文的文献
1
Organ-specific effects of curcumin on favipiravir-induced oxidative stress: renal benefit and hepatic risk.姜黄素对法匹拉韦诱导的氧化应激的器官特异性影响：对肾脏有益，对肝脏有风险。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 21. doi: 10.1007/s00210-025-04458-4.
2
Plausible mechanism of drug resistance and side-effects of COVID-19 therapeutics: a bottleneck for its eradication.新冠病毒治疗药物耐药性和副作用的可能机制：其根除的瓶颈。
Daru. 2024 Dec;32(2):801-823. doi: 10.1007/s40199-024-00524-z. Epub 2024 Jul 19.
3
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.关于COVID-19的药物制剂、免疫疗法和支持性疗法的全面综述。
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
4
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.在 COVID-19 早期使用法匹拉韦的临床抗病毒疗效（PLATCOV）：一项开放标签、随机、对照、自适应平台试验。
BMC Infect Dis. 2024 Jan 15;24(1):89. doi: 10.1186/s12879-023-08835-3.
5
Electroanalytical investigation and voltammetric quantification of antiviral drug favipiravir in the pharmaceutical formulation and urine sample using a glassy carbon electrode in anionic surfactant media.在阴离子表面活性剂介质中使用玻碳电极对药物制剂和尿液样本中的抗病毒药物法匹拉韦进行电分析研究和伏安法定量。
Turk J Chem. 2022 Feb 23;46(3):869-880. doi: 10.55730/1300-0527.3375. eCollection 2022.
6
The COVID-19, tuberculosis and HIV/AIDS: Ménage à Trois.新型冠状病毒肺炎、结核病和艾滋病：三者之间的关系。
Front Immunol. 2023 Jan 27;14:1104828. doi: 10.3389/fimmu.2023.1104828. eCollection 2023.
7
Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment.达芦那韦乙醇酸盐：将一种抗艾滋病毒药物用于新冠肺炎治疗的新用途。
Eur J Med Chem Rep. 2021 Dec;3:100013. doi: 10.1016/j.ejmcr.2021.100013. Epub 2021 Oct 22.
8
Structural Elucidation of Alkali Degradation Impurities of Favipiravir from the Oral Suspension: UPLC-TQ-ESI-MS/MS and NMR.UPLC-TQ-ESI-MS/MS 和 NMR 法研究口服液中磷酸奥司他韦降解杂质的结构
Molecules. 2022 Aug 31;27(17):5606. doi: 10.3390/molecules27175606.
9
Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal.超越疫苗：一瞥基于小分子和肽的抗 COVID-19 武器库。
J Biomed Sci. 2022 Sep 6;29(1):65. doi: 10.1186/s12929-022-00847-6.
10
Core shell stationary phase for a novel separation of some COVID-19 used drugs by UPLC-MS/MS Method: Study of grapefruit consumption impact on their pharmacokinetics in rats.用于通过超高效液相色谱-串联质谱法对一些新冠病毒用药进行新型分离的核壳固定相：研究葡萄柚摄入对大鼠体内这些药物药代动力学的影响。
Microchem J. 2022 Oct;181:107769. doi: 10.1016/j.microc.2022.107769. Epub 2022 Jul 15.
本文引用的文献
1
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.法匹拉韦治疗新型冠状病毒肺炎的实验性治疗：一项开放标签对照研究。
Engineering (Beijing). 2020 Oct;6(10):1192-1198. doi: 10.1016/j.eng.2020.03.007. Epub 2020 Mar 18.
2
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections.法匹拉韦，一种针对危及生命的 RNA 病毒感染的抗流感药物。
Pharmacol Ther. 2020 May;209:107512. doi: 10.1016/j.pharmthera.2020.107512. Epub 2020 Feb 22.
3
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
4
A novel coronavirus outbreak of global health concern.一场引发全球卫生关注的新型冠状病毒疫情。
Lancet. 2020 Feb 15;395(10223):470-473. doi: 10.1016/S0140-6736(20)30185-9. Epub 2020 Jan 24.
5
Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014.2014 年塞拉利昂接受法匹拉韦（T-705）治疗的埃博拉病毒病患者的临床和病毒学特征。
Clin Infect Dis. 2016 Nov 15;63(10):1288-1294. doi: 10.1093/cid/ciw571. Epub 2016 Aug 23.
6
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.法匹拉韦治疗埃博拉病毒病的实验性治疗（JIKI试验）：在几内亚进行的一项历史对照单臂概念验证试验。
PLoS Med. 2016 Mar 1;13(3):e1001967. doi: 10.1371/journal.pmed.1001967. eCollection 2016 Mar.
7
Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers.暴露后使用实验性抗病毒药物预防埃博拉病毒病：医护人员的病例系列研究。
Lancet Infect Dis. 2015 Nov;15(11):1300-4. doi: 10.1016/S1473-3099(15)00228-5. Epub 2015 Aug 25.
8
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model.在小动物模型中，用 T-705（法匹拉韦）成功治疗晚期埃博拉病毒感染。
Antiviral Res. 2014 May;105:17-21. doi: 10.1016/j.antiviral.2014.02.014. Epub 2014 Feb 26.
9
Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model.口服T-705（法匹拉韦）在小鼠模型中对吸入性埃博拉病毒感染的暴露后疗效。
Antiviral Res. 2014 Apr;104:153-5. doi: 10.1016/j.antiviral.2014.01.012. Epub 2014 Jan 24.
10
Favipiravir (T-705), a novel viral RNA polymerase inhibitor.法匹拉韦（T-705），一种新型的病毒 RNA 聚合酶抑制剂。
Antiviral Res. 2013 Nov;100(2):446-54. doi: 10.1016/j.antiviral.2013.09.015. Epub 2013 Sep 29.
Zotero 插件